Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Pfizer Inc. : Pfizer Will Remove Claims on Breast and Colon Health From Centrum Label -Reuters

share with twitter share with LinkedIn share with facebook
share via e-mail
07/05/2012 | 11:26pm CEST

Pfizer Inc. (>> Pfizer Inc.) said it will remove claims that its Centrum multivitamin supplements promote breast and colon health from labels over the next six months, following a complaint by a watchdog group, Reuters reported Thursday.

The company will also revise websites and advertising for Centrum, the report said.

The report said the Center for Science in the Public Interest sent a letter to Pfizer Chief Executive Ian Read in April outlining its complaints and threatening a lawsuit if the claims weren't removed.

In a statement, Pfizer said it "disagrees with CSPI's concerns, but has agreed to make these changes in order to fully resolve the issues raised by the organization," Reuters reported.

Full story at http://www.reuters.com/article/2012/07/05/pfizer-centrum-idUSL2E8I5BR820120705

Write to nymonitoring@dowjones.com

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER INC
12:27p PFIZER : locks down US approval for Besponsa
11:04a PFIZER : Thomas Wynn makes the leap out of the NIH and into a lead discovery pos..
06:04a PFIZER : U.S. pharmaceutical firms to extend investments in Egypt
08/18 PFIZER : Global Anal Fistula Treatment Market 2022 - Teva, Novartis, Pfizer, Roc..
08/18 PFIZER : Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the..
08/18 PFIZER : Receives U.S. FDA Approval F=for Besponsa (Inotuzumab Ozogamicin)
08/18 BRISTOL-MYERS SQUIBB AND PFIZER : to Highlight Commitment to Reducing the Risk o..
08/18 PFIZER : Receives u.s. fda approval for besponsa
08/17 PFIZER : FDA OKs Pfizer drug for rare, fast-killing type of leukemia
08/17 PFIZER : Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)
More news
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2017 52 721 M
EBIT 2017 19 844 M
Net income 2017 11 415 M
Debt 2017 23 771 M
Yield 2017 3,93%
P/E ratio 2017 17,44
P/E ratio 2018 15,13
EV / Sales 2017 4,14x
EV / Sales 2018 3,98x
Capitalization 194 554 M
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,5 $
Spread / Average Target 15%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%357 079
ROCHE HOLDING LTD.4.99%218 752
NOVARTIS8.84%218 545
PFIZER0.59%196 221